Century Therapeutics (IPSC) Enterprise Value (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Enterprise Value data on file, last reported at -$134.8 million in Q1 2026.

• On a quarterly basis, Enterprise Value rose 18.36% year-over-year to -$134.8 million in Q1 2026; TTM through Mar 2026 was -$134.8 million, a 18.36% increase from a year earlier, with the FY2025 full-year figure at -$168.6 million, up 10.96% from the prior year.
• Enterprise Value for Q1 2026 stood at -$134.8 million, up from -$168.6 million in the prior quarter.
• Over the last five years, Enterprise Value for IPSC reached as high as -$132.7 million in Q3 2025 and fell as low as -$378.8 million in Q2 2022.
• Historically, Enterprise Value has averaged -$217.3 million across 5 years, with a median of -$189.3 million in 2024.
• Across the five-year window, Enterprise Value sank 41.56% in 2022 and soared 58.71% in 2023, its largest moves.
• Year by year, Enterprise Value stood at -$315.5 million in 2022, then surged by 45.25% to -$172.7 million in 2023, then retreated by 9.58% to -$189.3 million in 2024, then advanced by 10.96% to -$168.6 million in 2025, then rose by 20.02% to -$134.8 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$134.8 million in Q1 2026, -$168.6 million in Q4 2025, and -$132.7 million in Q3 2025.